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Objectives: The present study was designed to study the effects of a single
intrapericardial injection of basic fibroblast growth factor on myocar-
dial vascular resistance and endothelium-dependent microvascular
dilatation in a porcine model of chronic myocardial ischemia and to
investigate the mechanism of ischemia-induced impairment of endothe-
lium-dependent vasodilatation. Methods: Yorkshire pigs underwent
ameroid constrictor placement on the left circumflex coronary artery.
At 3 weeks, animals were randomized to a single intrapericardial injec-
tion of saline solution (n = 10), 30 m g basic fibroblast growth factor (n =
10), or 2 mg basic fibroblast growth factor (n = 10). Myocardial vascu-
lar resistance in the normal (left anterior descending) and ischemic col-
lateral-dependent (left circumflex artery) territories (using colored
microspheres) and microvascular reactivity to adenosine diphosphate
and sodium nitroprusside were measured before treatment and 4 weeks
after treatment. The expression of inducible and endothelial nitric oxide
synthase was determined in normal and ischemic myocardium by means
of reverse transcriptase–polymerase chain reaction and Western analy-
sis, and the effect of nitric oxide on endothelium-dependent vasodilata-
tion was determined. Results: Compared with results in the control
group, treatment with basic fibroblast growth factor resulted in signifi-
cant improvement in left circumflex artery resistance and endothelium-
dependent vasodilatation, reflecting increased collaterals. Myocardial
ischemia was associated with increased expression of inducible nitric
oxide synthase with no change in endothelial nitric oxide synthase.
However, the nitric oxide donor sodium nitroprusside did not affect
endothelium-dependent vasodilatation to adenosine diphosphate.
Conclusions: A single intrapericardial bolus of basic fibroblast growth
factor may be a useful therapeutic strategy for the treatment of myocar-
dial ischemia in patients with coronary artery disease. Although chronic
myocardial ischemia is associated with increased expression of inducible
nitric oxide synthase, it does not appear to be the cause of altered
endothelial function. (J Thorac Cardiovasc Surg 1998;116:1022-8)
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T herapeutic angiogenesis is a novel approach to thetreatment of myocardial ischemia based on the use
of proangiogenic growth factors to induce the growth
and development of new blood vessels. Angiogenesis is
a complex process involving endothelial and smooth
muscle cell proliferation and migration, formation of
new capillaries, breakdown of existing extracellular
matrix, and deposition of new extracellular matrix.1 We
and others have shown that various heparin-binding
growth factors, including basic fibroblast growth factor
(bFGF),2-8 acidic fibroblast growth factor, and vascular
endothelial growth factor (VEGF),2,9-12 induce func-
tionally significant angiogenesis in chronic myocardial
ischemia. Given the typically long time course of new
collateral vessel development, most attempts to stimu-
late angiogenesis have used various methods of pro-
longed growth factor delivery, including gene therapy,
continuous infusions, repeated injections, or sustained-
release polymers to provide extended exposure to the
desired growth factor.2-5,7,9,12-15
Chronic myocardial ischemia is associated with
reduced endothelium-dependent microvascular dilata-
tion, which may be restored after growth factor therapy
that results in improved perfusion of the ischemic
zone.16-23 With growth factor treatment or reperfusion,
endothelium-dependent microvascular dilatation paral-
lels various other measures of angiogenesis, including
angiographic collaterals, microsphere flow, myocardial
vascularity by morphometric analysis, and restoration
of myocardial function.19-25. This recovery of endothe-
lium-dependent vasodilation may, in addition, reflect
recovery of endothelial function. Endothelium-inde-
pendent microvascular relaxation, however, is pre-
served even in the presence of severe chronic myocar-
dial ischemia.16,19,20,26 The purpose of the present study
was to determine the effects of a single intrapericardial
injection of bFGF in a porcine model of chronic
myocardial ischemia and to further investigate the
underlying mechanisms of the impairment of endothe-
lium-dependent microvascular dilatation in chronic
myocardial ischemia. An in vitro approach was used to
study vascular responses of coronary microvessels to
eliminate metabolic, autoregulatory, and other
extravascular influences.
Methods
Chronic myocardial ischemia model. Yorkshire pigs of
either sex weighing 15 to 18 kg were anesthetized with intra-
muscular ketamine (10 mg/kg) and inhalational halothane. By
sterile technique, a right popliteal cutdown was performed and
a 4F arterial catheter was inserted for blood sampling and
pressure monitoring. A left thoracotomy was performed
through the fourth intercostal space during mechanical venti-
lation. The pericardium was opened, and an ameroid constric-
tor of 2.5- to 2.75-mm internal diameter (matched to the diam-
eter of the artery) was placed around the proximal circumflex
(LCX) coronary artery.4,7,9 The pericardium was closed with
6-0 Prolene suture (Ethicon, Inc, Somerville, NJ), and the
chest was closed. A single dose of intravenous cefazolin (70
mg/kg) was given and intramuscular narcotic analgesics were
administered as needed. Animals were then allowed to recov-
er for 3 weeks (time sufficient for ameroid closure) before
growth factor delivery. Animals were treated according to
National Institutes of Health guidelines and the protocol was
approved by the Institutional Animal Care and Utilization
Committee of the Beth Israel Deaconess Medical Center.
Growth factor delivery. Three weeks after ameroid place-
ment, animals were anesthetized with intramuscular keta-
mine (10 mg/kg) and inhalational halothane. By sterile tech-
nique, a right femoral cutdown was performed and an 8F
arterial sheath was inserted for blood sampling, pressure
monitoring, and left heart catheterization. Coronary angiog-
raphy was then performed in multiple views with the use of a
7F JR4 diagnostic catheter (Cordis Corporation, Opa Locka,
Fla) to confirm the status of the LCX. After LCX occlusion
was documented, percutaneous subxiphoid pericardial access
was undertaken.
The animals were then randomized to three treatment
groups: (1) control: intrapericardial saline solution (n = 10);
(2) bFGF 30 m g: intrapericardial bFGF (n = 10); and (3) bFGF
2 mg: intrapericardial bFGF (n = 10).
Heparin (3 mg) was used in the vehicle for fibroblast
growth factor administration. At the end of the procedure, a
set of colored microspheres (blue) was injected into the left
atrium (via retrograde cannulation of the left atrium) to
obtain baseline (pre-treatment) myocardial vascular resis-
tance. The animals were then allowed to recover for 4 weeks.
Final study. Four weeks after intrapericardial treatment,
all animals underwent final evaluation. Pigs were anes-
thetized with intramuscular ketamine (10 mg/kg) and inhala-
tional halothane. By sterile technique, a left femoral cutdown
was performed and an 8F arterial sheath was inserted for
blood sampling, pressure monitoring, and left heart catheter-
ization. Myocardial vascular resistance at rest was deter-
mined with colored microspheres (yellow). Animals were
then put to death while anesthetized and the heart was
obtained for further analysis.
Coronary vascular resistance. Colored microspheres
spheres (15 ± 0.1 m m diameter, Triton Technology Inc, San
Diego, Calif) were used to determine coronary vascular resis-
tance before the start of treatment (blue) and at the time of
final study. For determination of coronary vascular resistance
3 and 7 weeks after ameroid placement, an angiographic
catheter was advanced into the left atrium through the mitral
valve. Catheter position was verified by injection of contrast
material into the left atrium. In addition, mean left atrial pres-
sure was recorded. A set of microspheres (6 · 106) was dilut-
ed in 10 mL of saline solution and injected into the left atrium
over 30 seconds. Reference blood samples were withdrawn
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with the use of a syringe pump at a constant rate of 5 mL/min
through the femoral artery. After study completion, the heart
was excised and regional myocardial vascular resistance was
determined by means of the following formula:
Resistance (mm Hg/mL/min/gm) = MAP/(Sample AU ·
Withdrawal rate/Reference AU · sample weight)
where MAP is mean arterial pressure and AU is optical
absorbance units.
Microvessel analysis. Coronary arterial microvessels (60-
180 m m in internal diameter) were dissected from the subepi-
cardial region of the LAD (normal) and collateral-dependent
LCX (ischemic) territories. Microvessels were placed in a
Plexiglas acrylic microvessel chamber (University of Iowa
Medical Instruments, Iowa City, Iowa), cannulated with dual
glass micropipettes measuring 30 to 80 m m in diameter, and
secured with 10-0 nylon monofilament suture (Ethicon,
Somerville, NJ). Oxygenated (95% oxygen, 5% carbon diox-
ide) Krebs buffer solution warmed to 37°C was continuously
circulated through the microvessel chamber with a reservoir
containing 100 mL. The vessels were pressurized to 40 mm
Hg in a no-flow state by means of a biuret manometer filled
with Krebs buffer solution.19-25,27 With an inverted micro-
scope (40· -200· , Olympus, Tokyo, Japan) connected to a
video camera, the vessel image was projected onto a black
and white television monitor (Hitachi Medical Corp, Tokyo,
Japan). An electronic dimension analyzer (Living System
Instrumentation, Burlington, Vt) was used to measure inter-
nal lumen diameter. Measurements were recorded with a
strip-chart recorder (Graphtec, Irvine, Calif). Vessels were
allowed to equilibrate for 30 minutes in Krebs buffer solution
before an intervention and for 15 minutes between applica-
tions of each drug. Microvessels were precontracted by 30%
to 60% of baseline with acetylcholine (10-7 to 10-6 mol/L).
Microvascular responses to adenosine diphosphate (ADP, an
endothelium-dependent vasodilator) and sodium nitroprus-
side (SNP, an endothelium-independent vasodilator) were
recorded. In addition, to investigate the potential effect of
basal nitric oxide (NO) production on endothelium-depen-
dent vasodilation, we measured the response of microvessels
to ADP in the presence of different concentrations of SNP
(10-6 and 10-7 mol/L) that would be associated with physio-
logic concentrations of NO.
Endothelial and inducible nitric oxide synthase expres-
sion. Endothelial (eNOS) and inducible nitric oxide synthase
(iNOS) expression were assessed in the normal and ischemic
myocardium to explore their role in the reduced endothelium-
dependent vasodilation seen with ischemia.
Reverse transcriptase–polymerase chain reaction. RNA
was isolated from normal (LAD) and ischemic (LCX)
myocardium by means of a commercially available kit (Trizol
kit, Life Technologies, Rockville, Md). RNA (0.5 m g per reac-
tion) was reverse transcribed with 20 U of Moloney murine
leukemia virus reverse transcriptase in 50 mmol/L Tris-HCl
(pH 8.3), 3 mmol/L MgCl2, 75 mmol/L KCl, 1 mmol/L
deoxynucleotide triphosphates, and 0.05 nmol 3´ primer. The
reaction was carried out at 37°C for 1 hour and then stopped
by heating the mixture to 70°C for 15 minutes to destroy
reverse transcriptase activity before the polymerase chain
reaction. Specific primers for eNOS and iNOS were designed
on the basis of previously published sequences (eNOS: 5´
[sense] primer: 5´-GCCTCGCTCTGAAAGA-3´,3´ [anti-
Fig 1. Myocardial vascular resistance in the normal (LAD) and collateral-dependent (LCX) territories at 3 weeks.
Four weeks after intrapericardial drug delivery, vascular resistance in the collateral-dependent LCX territory was
lower in bFGF-treated animals than in control animals. Data are shown as mean ± standard deviation. *Statistical
significance (P < .0017) compared with LAD at 3 weeks and LCX final compared with LCX at 3 weeks.
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sense] primer: 5´-TAAAGGTCTTCTTCCTGGTGATGCC-
3´—iNOS 5´ [sense] primer: 5´-GCCTCGCTCTGGAAAGA-
3´,3´ [antisense] primer: 5´-TCCATGCAGACAACCTT-3´).
Complementary DNA (cDNA) 5 m L was amplified for 35
cycles at 94°C for 1 minute, 55°C for 1 minute, and 72°C for
1 minute (melting, annealing, and extension temperatures,
respectively). Calibration was performed by co-amplification
of the same cDNA samples with primers for glyceraldehyde-
3-phosphate dehydrogenase as internal standard (5´ [sense]
primer: 5´-CCATGGAGGAAGGCTGGGG-3´ and 3´ [anti-
sense] primer: 5´-CAAAGTTGTCATGGATGACC-3´). After
amplification, polymerase chain reaction mixtures were elec-
trophoresed on 1.5% agarose gel containing ethidium bro-
mide, and polymerase chain reaction products were visualized
on an ultraviolet transilluminator and photographed. The
images were scanned and analyzed with the Molecular
Dynamics densitometric quantitative software (Molecular
Dynamics, Sunnyvale, Calif).
Western analysis. Proteins were extracted with a buffer
containing Tris-HCl (50 mmol/L, pH 7.5), NaCl (0.15
mol/L), ethyleneglycoltetraacetic acid (0.1 mmol/L), ethyl-
enediaminetetraacetic acid (0.1 mmol/L). Noninet P-40 (1%,
v/v), b -mercaptoethanol (0.1%, vol/vol), and protease in-
hibitors (10 m g/mL leupeptin, 10 m g/mL pepstatin A, 10
m g/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluo-
ride). Proteins were solubilized. Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis was performed with the
use of 8% polyacrylamide gels, and the proteins were then
transferred to a nitrocellulose membrane overnight at 4°C.
After being blocked, membranes were incubated for 1 hour
with the NOS–specific antibody (eNOS: polyclonal [rabbit]
anti-eNOS antibody; iNOS: polyclonal [rabbit] anti-iNOS
antibody (Affinity BioReagents, Inc, Golden, Colo) at room
temperature. Membranes were then washed 3 times in TBS-
0.1% Tween 20 and incubated with a horseradish-peroxi-
dase–conjugated anti-rabbit immunoglobulin G. Immuno-
reactive protein bands were visualized by means of the
enhanced chemiluminescence system (Amersham Corp,
Arlington Heights, Ill). Equal protein loading was then con-
firmed by membrane coumassie staining.
Statistical analysis. Data are expressed as mean ± standard
deviation. Vascular responses are expressed as percent relax-
ation of the acetylcholine-induced contraction. Continuous
variables were compared by unpaired or paired Student t test
and analysis of variance (Bonferroni-corrected t tests were
used for multiple group comparisons).
Fig 2. Endothelium-independent (SNP, A) and endothelium-dependent (ADP, B) vasodilatation in the normal
(LAD) myocardium. Responses are expressed as percent relaxation of acetylcholine-induced precontraction.
Fig 3. Endothelium-independent (SNP, A) and endothelium-dependent (ADP, B) vasodilation in the collateral-
dependent LCX myocardium showing preserved response to SNP with impaired response to ADP, restored by
bFGF treatment. Responses are expressed as percent relaxation of acetylcholine-induced precontraction.
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Results
Thirty animals had placement of an ameroid occlud-
er over the LCX coronary artery, randomized to each of
the 3 treatment groups with 10 animals in each group.
No significant hemodynamic effect of intrapericardial
bFGF administration was noted, with no change in
blood pressure, heart rate, or left atrial pressure.
Myocardial vascular resistance. To evaluate the
angiogenic potential of intrapericardial bFGF in chron-
ic myocardial ischemia, we measured regional myocar-
dial vascular resistance at different time points using
colored microspheres. Three weeks after implantation
of ameroid occluders, at the time of intrapericardial
drug delivery, myocardial vascular resistance in the col-
lateral-dependent LCX territory was similar in all treat-
ment groups (Fig 1, P = .8) and was significantly high-
er than resistance in the LAD territory (LCX resistance:
92.84 ± 34.9 mm Hg/mL per minute per gram; LAD
resistance: 64.84 ± 19.5 mm Hg/mL per minute per
gram; P < .0001). Four weeks after intrapericardial drug
delivery, LCX resistance was significantly lower in
bFGF-treated animals than in control animals {Fig 1,
LCX vascular resistance 82.54 ± 16.4 mm Hg/mL per
minute per gram in control animals vs 72.24 ± 13.8 mm
Hg/mL per minute per gram in the 30-m g bFGF group
[P = .08] and 67.84 ± 20.0 and 1.25 ± 0.15 mm Hg/mL
per minute per gram in the 2-mg bFGF group [P = .03]).
Microvessel analysis. Coronary arterial microvessels
were studied for response to ADP (endothelium-depen-
dent vasodilator) and SNP (endothelium-independent
vasodilator). Similar concentrations of acetylcholine
were required in LCX and LAD microvessels to attain
similar (45% ± 5% of baseline) degrees of precontrac-
tion values. Microvascular response to SNP was similar
in the LAD and LCX territories for all groups (Figs 2
and 3). However, endothelium-dependent (ADP) vasodi-
lation was normal in the LAD (Fig 2) but not LCX (Fig
3) distribution in control animals, indicating dysfunc-
tional endothelium in the ischemic zone. Administration
of bFGF 30 m g (analysis of variance, P = .03) and bFGF
2 mg (P = .0005) improved endothelium-dependent
vasodilation in the LCX epicardium with almost normal
relaxation in the 2-mg bFGF group (Fig 3).
Endothelium-dependent vasodilation is NO-depen-
dent and is inhibited by Nw-nitro-L-arginine methyl
ester.19-22,24 To investigate the mechanism of ischemia-
induced impairment of endothelium-dependent relax-
ation, we studied the expression of iNOS and eNOS in
normal and ischemic myocardium. By Western analy-
sis, the ischemic myocardium had a 2.74 ± 0.7–fold
increase in the level of iNOS protein over normal
myocardium, with no change in eNOS level (Fig 4).
The expression of iNOS mRNA was also increased in
ischemic myocardium (2.3 ± 0.6 times) as compared
with normal myocardium according to reverse tran-
scriptase–polymerase chain reaction. However, eNOS
mRNA level was unchanged. To determine whether the
increased iNOS expression in ischemic tissue and the
resultant increase in basal NO production may inhibit
eNOS activity28 and reduce endothelium-dependent
vasodilatation, we measured the microvascular re-
sponse to ADP in the presence of 2 different concen-
trations (10–6 and 10–7 mol/L) of SNP, an NO donor
(Fig 5). SNP did not have any significant effect on the
response of microvessels to ADP, nor did these con-
centrations affect the response of vessels to additional
SNP if the degree of precontraction was normalized.
Discussion
Previous studies have demonstrated that administra-
tion of bFGF3-8,29,30 or VEGF2,9-12 results in significant
Fig 4. Expression of iNOS and eNOS in ischemic and normal
myocardium by reverse transcriptase–polymerase chain reac-
tion (RT-PCR) and Western analysis.
Fig 5. Endothelium-dependent vasodilatation (ADP) was not
affected by the presence of 2 different concentrations (10–6
and 10–7 mol/L) of SNP, an NO donor. Responses are ex-
pressed as percent relaxation of acetylcholine-induced pre-
contraction.
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angiogenesis in several models of myocardial ischemia.
However, most attempts to stimulate angiogenesis have
used various methods of prolonged growth factor deliv-
ery, including gene therapy, continuous infusions,
repeated injections, or sustained-release polymers to
provide extended exposure to the desired cytokine. The
applicability of these measures to patients is limited.
Intrapericardial bFGF treatment resulted in improve-
ment (reduction) in myocardial vascular resistance,
which is collateral dependent in the ameroid constrictor
model with an occluded LCX. This reduction in vascu-
lar resistance reflects growth of new collaterals. In
addition, intrapericardial bFGF restored endothelium-
dependent microvascular vasodilatation. These effects
are similar to the previously reported perivascular sus-
tained-release bFGF and VEGF effects4,21,22 in this ani-
mal model.
The present study demonstrates a reduction in
myocardial vascular resistance in the ischemic collater-
al-dependent LCX distribution and normalization of
LCX endothelium-dependent microvascular relaxation
in a model of chronic myocardial ischemia in which a
single intrapericardial injection of bFGF was used. We
have previously shown that bFGF (10-100 m g) incorpo-
rated into heparin-alginate microspheres (for sustained
delivery) and implanted on the epicardial surface of the
occluded LCX results in significant improvement in
myocardial perfusion and endothelium-dependent
vasodilation in the setting of chronic myocardial
ischemia.4,30 This relatively invasive delivery method,
however, may not be applicable to the majority of
patients with coronary artery disease. Thus the single
intrapericardial approach is a more attractive strategy
for therapeutic angiogenesis.
Because endothelium-dependent vasodilatation is an
NO-dependent mechanism, we studied the expression
of 2 isoforms of NOS in normal and ischemic
myocardium. Myocardial ischemia results in increased
expression of iNOS protein and mRNA without any
change in eNOS expression. Therefore ischemia-
induced impairment of endothelium-dependent vasodi-
latation cannot be attributed to changes in the expres-
sion of eNOS in ischemic tissue. The increased
expression of iNOS may result in increased basal NO
production, which has been shown to inhibit partially
purified eNOS.28 However, endothelium-dependent
vasodilatation was not affected by SNP (an NO donor),
negating this hypothesis. Therefore the mechanism of
ischemia-induced impairment of endothelium-depen-
dent vasodilatation may be unrelated to the increased
expression of iNOS. Intrapericardial bFGF restores
endothelium-dependent vasodilatation, which may
indicate restoration of normal endothelial function ow-
ing to restoration of normal myocardial blood flow,
coronary perfusion pressure, or other mechanisms not
examined in this study.
Conclusion 
We conclude that a single intrapericardial injection of
bFGF in a porcine model of chronic myocardial
ischemia results in an improvement in myocardial vas-
cular resistance (reflecting increased collateralization of
the ischemic myocardium) and endothelium-dependent
microvascular dilatation. Thus single-bolus intraperi-
cardial bFGF administration may be a useful therapeu-
tic strategy for the treatment of myocardial ischemia in
patients with coronary artery disease. Although chronic
myocardial ischemia is associated with increased
expression of iNOS, its relationship to impaired endo-
thelium-dependent relaxation is uncertain.
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Discussion
Dr Edward D. Verrier (Seattle, Wash). This is an impor-
tant study, because so many of the studies with angiogenic
factors show proliferation of small vessels, but the relation-
ship between anatomic changes showing angiogenesis and
the functional recovery of muscle have been lacking.
Combining that information with the ease of administration
of this growth factor into the pericardium makes this study
particularly important.
Dr Verdi J. DiSesa (Chicago, Ill). You have obviously
done a lot of nice work. Unfortunately, you tried to present a
great deal of data very quickly, and I found myself having dif-
ficulty being convinced of an argument I wanted to believe.
You did not define collateral index. You did not explain how
you measured blood flow in the LCX distribution. Those
points are crucial to what Dr Verrier was just saying, that is,
demonstrating functional importance of these new capillaries
that you hypothesize the growth factor was producing. 
Dr Laham. The collateral index has been published previ-
ously and is a measure of the angiographic distribution and
the angiographic filling of collaterals. Colored microspheres
are used to determine flow, as well as resistance. The func-
tional improvement and perfusion are determined by magnetic
resonance imaging. All of these methods have been previous-
ly published extensively in the literature.
Dr Jacob Kolff (Johnstown, Pa). I would like to use angio-
statin somehow or see what effect it would have. What if our
philosophy is that the act of producing ischemia already max-
imally stimulates neoangiogenesis? Perhaps that can be
stopped by applying some kind of an antivascular or neovas-
cularization drug or enzyme. That way you would stop the
collateralization, and perhaps you could show that these fac-
tors are in fact important if they are on the positive side of
producing this neovascularization. 
Dr Laham. It does seem from all our previous work that
supplementation of these growth factors is necessary in most
of these studies. It is probable that the ischemic response of
the normal myocardium produces bFGF and VEGF. This has
been demonstrated, but not to an extent that is sufficient for
the growth of collaterals that would lead to significant
improvement in function. The supplementation of these
growth factors has been extensively studied in a sustained-
release form. This is now an established technique, and phase
1 and phase 2 clinical trials in patients are now being con-
ducted. The preliminary results are very promising. However,
this study was designed to evaluate a single intrapericardial
delivery, which was shown to be comparable with the sus-
tained-release formulations that we and others had previously
used. That is really the novelty of the study.
